



Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/733,168
		Filing Date	December 8, 2000
		First Named Inventor	Frey II
		Group Art Unit	1645
		Examiner Name	Not yet assigned
Sheet 1 of 3	Attorney Docket Number	1670.002 (5784-54)	

RECEIVED

AUG 02 2001

TECH CENTER 1600/2900

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	4,479,932		Bodor	10-30-1984	
	2	4,746,508		Carey <i>et al.</i>	05-24-1988	
	3	4,857,316		Eppstein	08-15-1989	
	4	5,145,677		von Eichborn <i>et al.</i>	09-08-1992	
	5	5,482,706		Igari <i>et al.</i>	01-09-1996	
	6	5,624,898		Frey II	04-29-1997	
	7	5,676,942		Testa <i>et al.</i>	10-14-1997	
	8	5,853,763		Tice <i>et al.</i>	12-29-1998	
	9	6,048,843		Tóth	04-11-2000	
	10	6,060,450		Soos <i>et al.</i>	05-09-2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code (if known) ⁵				
	11	EP	0 504 263	B1	RAMSEY FOUNDATION	09-23-1992		
	12	JP	7041428	A	TEIJIN LTD.	02-10-1995		
	13	WO	91/07947	A1	RAMSEY FOUNDATION	06-13-1991		
	14	WO	00/44350	A1	IDEA AG	08-03-2000		
	15	SU	1139444	A	A.Н. Ирецкий	02-15-1985		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place an "X" here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Sheet 2 of 3		Application Number	09/733,168
		Filing Date	December 8, 2000
		First Named Inventor	Frey II
		Group Art Unit	1645
		Examiner Name	Not yet assigned
		Attorney Docket Number	1670.002 (5784-34)
NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	16	BARBARO <i>et al.</i> (1999) "Intravenous Recombinant Interferon-Beta versus Interferon-Alpha-2b and Ribavirin in Combination for Short-Term Treatment of Chronic Hepatitis C Patients Not Responding to Interferon-Alpha," <i>Scand. J. Gastroenterol.</i> 34(9): 928-933.	
	17	BOCCI <i>et al.</i> (1988) "The Lymphatic Route. V. Distribution of Human Natural Interferon- β in Rabbit Plasma and Lymph," <i>Journal of Interferon Research</i> 8(5): 633-640.	
	18	CHIEN <i>et al.</i> (1989) "Nasal Systemic Drug Delivery," <i>Modern Pharmaceutics</i> 39: 18-19, 44-49, 56-59, 82-85, 292-293.	
	19	CUI (2000) "A Plasmid Construct Encoding Murine Interferon Beta Antagonizes the Replication of Herpes Simplex Virus Type I <i>In Vitro</i> and <i>In Vivo</i> ," <i>J. Neuroimmunology</i> 108: 92-102.	
	20	EPPSTEIN <i>et al.</i> (1988) "Alternative Delivery Systems for Peptides and Proteins as Drugs," <i>CRC Critical Reviews in Therapeutic Drug Carrier Systems</i> 5(2): 99-139.	
	21	GEIGER (1997) "Interferon- γ Protects against Herpes Simplex Virus Type 1-Mediated Neuronal Death," <i>Virology</i> 238: 189-197.	
	22	GOPINATH <i>et al.</i> (1978) "Target Site of Intranasally Sprayed Substances and Their Transport Across the Nasal Mucosa: A New Insight into the Intranasal Route of Drug-Delivery," <i>Current Therapeutic Research</i> 23(5): 596-607.	
	23	KAKIZAKI <i>et al.</i> (1999) "Evaluation of Twice-Daily Administration of Interferon- β for Chronic Hepatitis C," <i>J. Viral Hepatitis</i> 6: 315-319.	
	24	KIDA <i>et al.</i> (1993) "CSF Drains Directly from the Subarachnoid Space into Nasal Lymphatics in the Rat. Anatomy, Histology and Immunological Significance," <i>Neuropathology and Applied Neurobiology</i> 19: 480-488.	
	25	LEE <i>et al.</i> (1988) "Intranasal Delivery of Proteins and Peptides," <i>BioPharm.</i> pp. 30-37.	
	26	LEIB <i>et al.</i> (1999) "Interferons Regulate the Phenotype of Wild-type and Mutant Herpes Simplex Viruses <i>In Vivo</i> ," <i>J. Exp. Med.</i> 189: 663-672.	
	27	MINAGAWA <i>et al.</i> (1997) "Suppression of Infectious Virus Spread and Corneal Opacification by the Combined Use of Recombinant Interferon Beta and Interleukin-10 Following Corneal Infection with Herpes Simplex Virus-1 in Mice," <i>Antiviral Research</i> 36: 99-105.	
Examiner Signature	Date Considered		

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO

**INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/733,168
Filing Date	December 8, 2000
First Named Inventor	Frey II
Group Art Unit	1645
Examiner Name	Not yet assigned
Attorney Docket Number	1670.002 (5784-54)

RECEIVED

AUG 02 2001

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	28	PELIDOU (2000) "Intranasal Administration of Recombinant Mouse Interleukin-12 Increases Inflammation and Demyelination in Chronic Experimental Autoimmune Neuritis in Lewis Rats," <i>Scand. J. Immunol.</i> 51: 25-35.	
	29	PERIDOU <i>et al.</i> (2000) "Enhancement of Acute Phase and Inhibition of Chronic Phase of Experimental Autoimmune Neuritis in Lewis Rats by Intranasal Administration of Recombinant Mouse Interleukin 17: Potential Immunoregulatory Role," <i>Experimental Neurology</i> 163: 165-172.	
	30	SHIP <i>et al.</i> (1999) "Treatment of Primary Sjögren's Syndrome with Low-Dose Natural Human Interferon- α Administered by the Oral Mucosal Route: A Phase II Clinical Trial," <i>J. Interferon and Cytokine Res.</i> 19: 943-951.	
	31	SMITH <i>et al.</i> (1987) "Intranasally Administered Alpha/Beta Interferon Prevents Extension of Mouse Hepatitis Virus, Strain JHM, into the Brains of BALB/cByJ Mice," <i>Antiviral Research</i> 8: 239-245.	
	32	THORNE <i>et al.</i> (date unknown) "Quantitative Assessment of Protein Transport to the Rat Olfactory Bulb Following Intranasal Administration: Implications for Drug Delivery," <i>Paper for Dept. of Neurology, St. Paul Ramsey Medical Ctr.</i> (20 pages)	
	33	XIAO <i>et al.</i> (1998) "Suppression of Acute and Protracted-Relapsing Experimental Allergic Encephalomyelitis by Nasal Administration of Low-Dose IL-10 in Rats," <i>J. Neuroimmuno.</i> 84: 230-237.	
Examiner Signature			Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. RTA01/2096206v1